Merck Lifts Its 2026 Profit Outlook To $2.77-$2.82 A Share Despite A Third-Quarter Earnings Dip
Third-quarter adjusted earnings per share fell to $2.49 from $2.58, yet the drugmaker raised its full-year range.
Merck raised its full-year adjusted earnings forecast to $2.77 to $2.82 a share, up from $2.66 to $2.76, even as third-quarter adjusted earnings slipped to $2.49 from $2.58 a year earlier, the company said Thursday in an 8-K filing. A one-time $0.12-per-share licensing charge and heavier research and launch spending weighed on the quarter.
Sales up, earnings down
Merck, a health care company that makes prescription medicines, vaccines and animal health products, reported third-quarter sales of $18.1 billion, up 5% (4% excluding currency effects). Earnings per share under standard accounting fell 12% to $2.04, from $2.32.
Both the standard and adjusted figures carry the $0.12 charge tied to a global license agreement with SciBrunch for MK-2690, a preclinical oral cancer drug candidate. Last year's third quarter included a $0.10-per-share milestone payment to LaNova Medicines.
Research and development spending rose 7% to $4.5 billion, including a $400 million SciBrunch charge, offset in part by a $200 million reduction tied to a funding agreement with Blackstone Life Sciences. Selling, general and administrative costs rose 10% to $2.9 billion on higher administrative and launch promotion costs. Standard gross margin fell to 72.9% from 77.7%.
Keytruda and Winrevair carry the quarter
Keytruda and its subcutaneous version Keytruda Qlex brought in $8.6 billion, up 6%, including $830 million from Qlex. Winrevair sales rose 93% to $694 million, and Welireg climbed 56% to $307 million.
Gardasil sales rose 14% to $1.995 billion. Januvia and Janumet fell 39% to $380 million on generic competition, and Bridion sank 67% to $144 million for the same reason. Animal Health sales rose 4% to $1.7 billion.
The company said purchase timing added about $550 million to pharmaceutical sales growth.
What the new guidance says
Merck now expects 2026 sales of $66.8 billion to $67.3 billion, narrowing a range that began at $66.3 billion. Its adjusted tax rate forecast dropped to 32.0% to 33.0% from 35.0% to 36.0%, and operating expense guidance rose to $42.4 billion to $42.9 billion.
The EPS range includes one-time charges of $3.62 a share for the Cidara acquisition, $2.31 for Terns and the new $0.12 for SciBrunch, which was not previously in the outlook.
Chairman and CEO Robert M. Davis said the oncology advances shown at ESMO "further clinically de-risk the substantial long-term opportunity of our late-phase pipeline." The FDA has set a June 15, 2027 target decision date for sac-TMT in endometrial cancer, though Merck said it is in talks with the agency and hopes for earlier approval.
Merck holds its earnings call at 9 a.m. EDT Thursday.
Sources
- 8-K Filing — Merck & Co., Inc. (MRK) — SEC EDGAR
- Exhibit tm2628203d1_ex99-1.htm — Merck & Co., Inc. 8-K exhibit — SEC EDGAR
- Exhibit tm2628203d1_ex99-2.htm — Merck & Co., Inc. 8-K exhibit — SEC EDGAR
- Pharma giants Merck, Eli Lilly face earnings health check (MRK:NYSE) | Seeking Alpha — seekingalpha.com
- Merck (MRK) Gains Fresh Oncology Backing As Valuation Debate Heats Up — Yahoo Finance
- Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck’s Q3 Results on Oct. 29 — Yahoo Finance
- Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts — Yahoo Finance
- Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline — businesswire.com